Moderna mRNA Melanoma Vaccine Plus Keytruda Shows Phase 3 Benefit
On Wednesday, August 19, 2026, CBS reported that a Phase 3 trial found Moderna's personalized mRNA melanoma vaccine given with Merck's Keytruda kept patients cancer-free longer than Keytruda alone.[1]
The trial enrolled more than 1,100 people with advanced-stage melanoma whose tumors had invaded deeply or reached lymph nodes.[1] Each vaccine dose was personalized by sequencing a patient's tumor, using artificial intelligence to pick mutations and encoding those targets in synthetic mRNA.[1] CBS described Keytruda as lifting an 'invisibility cloak' from cancer cells while the mRNA vaccine trains the immune system, likening the vaccine's role to giving a 'scent' to a bloodhound.[1]
All patients had their tumors surgically removed and received standard Keytruda; those also given the mRNA vaccine remained cancer-free longer than patients who got Keytruda alone.[1] Melanoma is the fifth most commonly diagnosed cancer in the United States, with about 112,000 new cases and an estimated 8,500 deaths projected in 2026.[1]
Show source details & analysis (2 sources)
📌 Key Facts
- On Wednesday, August 19, 2026, CBS reported that the Phase 3 trial enrolled more than 1,100 people with advanced-stage melanoma whose tumors had invaded deeply or reached lymph nodes.
- Each dose of Moderna's melanoma vaccine is personalized by sequencing a patient's tumor, using artificial intelligence to select which mutations to target, and encoding those targets in synthetic mRNA.
- CBS describes the mechanism as Merck's Keytruda lifting an "invisibility cloak" from cancer cells while the mRNA vaccine trains the immune system, likening the vaccine's role to giving a "scent" to a bloodhound.
- The report says patients whose tumors were surgically removed and who received standard Keytruda plus the mRNA vaccine remained cancer-free longer than those who received Keytruda alone.
- CBS notes that melanoma is the fifth most commonly diagnosed cancer in the United States, with about 112,000 new cases and an estimated 8,500 deaths projected in 2026.
📰 Source Timeline (2)
Follow how coverage of this story developed over time
- On Wednesday, August 19, 2026, CBS detailed that the Phase 3 trial enrolled more than 1,100 people with advanced-stage melanoma whose tumors had invaded deeply or reached lymph nodes.
- The article explains that each dose of Moderna's melanoma vaccine is personalized by sequencing a patient's tumor, using artificial intelligence to select which mutations to target, and encoding those targets in synthetic mRNA.
- CBS describes the mechanism of action as a combination of Merck's Keytruda lifting an "invisibility cloak" from cancer cells and the mRNA vaccine training the immune system, likened to giving a "scent" to a bloodhound.
- The report reiterates that all patients in the trial had their tumors surgically removed and received standard Keytruda; those additionally given the mRNA vaccine remained cancer-free longer than those on Keytruda alone.
- CBS notes melanoma is the fifth most commonly diagnosed cancer in the United States, with about 112,000 new cases and an estimated 8,500 deaths projected this year.